[{"orgOrder":0,"company":"Recordati","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Acquisition","leadProduct":"Sutimlimab","moa":"Complement C1s","graph1":"Hematology","graph2":"Approved FDF","graph3":"Recordati","amount2":1.0800000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":1.0800000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Recordati \/ Recordati","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Recordati"},{"orgOrder":0,"company":"Recordati","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ITALY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Siltuximab","moa":"Interleukin-6","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recordati \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recordati \/ Inapplicable"},{"orgOrder":0,"company":"Recordati","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Inapplicable"},{"orgOrder":0,"company":"Recordati","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Inapplicable"},{"orgOrder":0,"company":"Recordati","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Inapplicable"},{"orgOrder":0,"company":"Recordati","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Inapplicable"},{"orgOrder":0,"company":"Recordati","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Inapplicable"},{"orgOrder":0,"company":"Recordati","sponsor":"Amarin","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Recordati","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.17999999999999999,"dosageForm":"Oral Capsule","sponsorNew":"Recordati \/ Recordati","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Recordati"},{"orgOrder":0,"company":"Recordati","sponsor":"Tolmar","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Leuprolide Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Recordati","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Recordati \/ Tolmar","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Tolmar"},{"orgOrder":0,"company":"Recordati","sponsor":"Eusa Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Recordati","amount2":0.84999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.84999999999999998,"dosageForm":"Infusion","sponsorNew":"Recordati \/ Recordati","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Recordati"},{"orgOrder":0,"company":"Recordati","sponsor":"ARS Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ITALY","productType":"Hormone","year":"2023","type":"Acquisition","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Recordati \/ ARS Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ ARS Pharmaceuticals"},{"orgOrder":0,"company":"Recordati","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Siltuximab","moa":"Interleukin-6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recordati \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Recordati \/ Syneos Health"},{"orgOrder":0,"company":"Recordati","sponsor":"Recordati","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recordati \/ Recordati","highestDevelopmentStatusID":"8","companyTruncated":"Recordati \/ Recordati"},{"orgOrder":0,"company":"Recordati","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Siltuximab","moa":"Interleukin-6","graph1":"Oncology","graph2":"Phase II","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recordati \/ Recordati","highestDevelopmentStatusID":"8","companyTruncated":"Recordati \/ Recordati"},{"orgOrder":0,"company":"Recordati","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pasireotide Diaspartate","moa":"Somatostatin receptor 5 | Somatostatin receptor 3 | Somatostatin receptor 2 | Somatostatin receptor 1","graph1":"Endocrinology","graph2":"Phase II","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recordati \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recordati \/ Inapplicable"},{"orgOrder":0,"company":"Recordati","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pasireotide","moa":"Somatostatin receptor 5","graph1":"Endocrinology","graph2":"Phase II","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recordati \/ Recordati","highestDevelopmentStatusID":"8","companyTruncated":"Recordati \/ Recordati"}]

Find Clinical Drug Pipeline Developments & Deals by Recordati

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Under the licensing agreement, Recordati will be responsible for commercialization of Vazkepa (Icosapent Ethyl) in Europe. It is being indicated to reduce the risk of myocardial infarction, stroke.

                          Product Name : Vascepa

                          Product Type : Other Small Molecule

                          Upfront Cash : $25.0 million

                          June 24, 2025

                          Lead Product(s) : Icosapent Ethyl

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Recipient : Amarin

                          Deal Size : $175.0 million

                          Deal Type : Licensing Agreement

                          blank

                          02

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Isturisa (osilodrostat phosphate) is approved for the treatment of endogenous hypercortisolemia in adults with Cushing’s syndrome.

                          Product Name : Isturisa

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 16, 2025

                          Lead Product(s) : Osilodrostat Phosphate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          November 08, 2024

                          Lead Product(s) : Siltuximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Memorial Sloan Kettering Cancer Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Recordati will acquire the global rights to Enjaymo (sutimlimab), a biologic and the only approved targeted product for cold agglutinin disease, a rare B-cell lymphoproliferative disorder.

                          Product Name : Enjaymo

                          Product Type : Antibody

                          Upfront Cash : $825.0 million

                          April 10, 2024

                          Lead Product(s) : Sutimlimab

                          Therapeutic Area : Hematology

                          Highest Development Status : Approved FDF

                          Recipient : Sanofi

                          Deal Size : $1,075.0 million

                          Deal Type : Acquisition

                          blank

                          05

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          March 06, 2024

                          Lead Product(s) : Pasireotide

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II

                          Recipient : Memorial Sloan Kettering Cancer Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          July 03, 2023

                          Lead Product(s) : Pasireotide Diaspartate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Under the agreement, ARS Pharmaceuticals Reacquires commercial rights to neffy (ARS-1) in the European region. Neffy is an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions leading to ...

                          Product Name : Neffy

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          February 22, 2023

                          Lead Product(s) : Epinephrine

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved FDF

                          Sponsor : ARS Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          08

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Isturisa (osilodrostat phosphate) is an oral inhibitor of 11β-hydroxylase (CYP11B1), which catalyses the final step of cortisol synthesis in the adrenal glands. Isturisa® is available as 1 mg, 5 mg and 10 mg film-coated tablets.

                          Product Name : Isturisa

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 31, 2022

                          Lead Product(s) : Osilodrostat Phosphate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : ISTURISA (osilodrostat), is a cortisol synthesis inhibitor indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.

                          Product Name : Isturisa

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 06, 2022

                          Lead Product(s) : Osilodrostat Phosphate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          October 18, 2021

                          Lead Product(s) : Dinutuximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : IKF Nordwest

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank